ELAN
ACHAT TOTAL: 55 000 titres (~1 281 870,00 $ US)
- Insiders
- Kurzius Lawrence Erik, Harrington Michael J, Herendeen Paul
- Total bought
- $1,281,870
- Total sold
- —
- Last activity
- 2026-08-20
- Last synced
-
2026-08-26 03:23:35
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
ELAN presents a meaningful event-driven signal — a coordinated insider cluster buy of ~$1.28M, a fresh FDA EUA for CLiK Extra, and 10% Q2 revenue growth — that justifies attention despite mixed fundamentals.
The first sentence of the analysis written for ELAN on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 43.5% | 43.0% | 43.9% | 44.7% | 43.6% | |
| Ebit Margin | -0.1% | 18.6% | -20.8% | 4.2% | -6.4% | |
| Ebitda Margin | 14.3% | 33.5% | -5.1% | 19.6% | 8.6% | |
| Operating Profit Margin | 5.3% | 5.7% | 7.4% | 8.7% | 6.4% | |
| Pretax Profit Margin | -4.8% | 11.0% | -27.1% | -1.6% | -12.0% | |
| Continuous Operations Profit Margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | |
| Net Profit Margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | |
| Bottom Line Profit Margin | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | |
| Current Ratio | 2.165 | 2.445 | 2.745 | 1.927 | 1.988 | |
| Quick Ratio | 1.078 | 1.248 | 1.347 | 1.023 | 1.155 | |
| Solvency Ratio | 0.066 | 0.153 | -0.066 | 0.074 | 0.026 | |
| Cash Ratio | 0.341 | 0.356 | 0.284 | 0.203 | 0.387 | |
| Price To Earnings Ratio | -48.149 | 17.809 | -5.960 | -81.467 | -29.258 | |
| Price To Earnings Growth Ratio | 0.285 | -0.140 | -0.004 | 0.964 | 1.239 | |
| Forward Price To Earnings Growth Ratio | 0.285 | -0.140 | -0.004 | 0.964 | 1.239 | |
| Price To Earnings Diluted Ratio | -48.149 | 17.809 | -5.960 | -81.467 | -29.258 | |
| Price To Earnings Diluted Growth Ratio | 0.285 | -0.140 | -0.004 | 0.964 | 1.239 | |
| Price To Book Ratio | 1.716 | 0.981 | 1.179 | 0.819 | 1.842 | |
| Price To Sales Ratio | 2.383 | 1.348 | 1.661 | 1.353 | 2.902 | |
| Price To Free Cash Flow Ratio | 39.555 | 15.184 | 62.695 | 22.265 | 48.345 | |
| Price To Operating Cash Flow Ratio | 20.060 | 11.058 | 27.067 | 13.201 | 28.627 | |
| Debt To Assets Ratio | 0.301 | 0.343 | 0.402 | 0.377 | 0.383 | |
| Debt To Equity Ratio | 0.614 | 0.709 | 0.928 | 0.801 | 0.842 | |
| Debt To Capital Ratio | 0.380 | 0.415 | 0.481 | 0.445 | 0.457 | |
| Long Term Debt To Capital Ratio | 0.376 | 0.412 | 0.480 | 0.428 | 0.445 | |
| Financial Leverage Ratio | 2.040 | 2.069 | 2.308 | 2.125 | 2.195 | |
| Working Capital Turnover Ratio | 2.507 | 2.183 | 2.360 | 2.753 | 3.211 | |
| Operating Cash Flow Ratio | 0.351 | 0.411 | 0.218 | 0.266 | 0.293 | |
| Operating Cash Flow Sales Ratio | 0.119 | 0.122 | 0.061 | 0.102 | 0.101 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | 0.728 | 0.432 | 0.593 | 0.592 | |
| Debt Service Coverage Ratio | 2.272 | 3.496 | -0.825 | 1.335 | 0.891 | |
| Interest Coverage Ratio | 1.145 | 0.740 | 1.177 | 1.500 | 1.152 | |
| Short Term Operating Cash Flow Coverage Ratio | 7.568 | 12.295 | 7.132 | 1.165 | 1.643 | |
| Operating Cash Flow Coverage Ratio | 0.139 | 0.125 | 0.047 | 0.077 | 0.076 | |
| Capital Expenditure Coverage Ratio | 2.029 | 3.680 | 1.760 | 2.457 | 2.452 | |
| Dividend Paid And Capex Coverage Ratio | 2.029 | 3.680 | 1.760 | 2.457 | 2.452 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 21.754 | 6.605 | -56.952 | 13.231 | 47.696 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 43.5% | ▲0.5% | ▼-0.2% |
| Ebit Margin | -0.1% | ▼-18.7% | ▲0.8% |
| Ebitda Margin | 14.3% | ▼-19.2% | ▲0.1% |
| Operating Profit Margin | 5.3% | ▼-0.3% | ▼-1.4% |
| Pretax Profit Margin | -4.8% | ▼-15.7% | ▲2.1% |
| Continuous Operations Profit Margin | -4.9% | ▼-12.5% | ▲2.5% |
| Net Profit Margin | -4.9% | ▼-12.5% | ▲2.5% |
| Bottom Line Profit Margin | -4.9% | ▼-12.5% | ▲2.5% |
| Current Ratio | 2.165 | ▼-0.280 | ▼-0.089 |
| Quick Ratio | 1.078 | ▼-0.170 | ▼-0.093 |
| Solvency Ratio | 0.066 | ▼-0.088 | ▲0.015 |
| Cash Ratio | 0.341 | ▼-0.015 | ▲0.027 |
| Price To Earnings Ratio | -48.149 | ▼-65.958 | ▼-18.744 |
| Price To Earnings Growth Ratio | 0.285 | ▲0.425 | ▼-0.184 |
| Forward Price To Earnings Growth Ratio | 0.285 | ▲0.425 | ▼-0.184 |
| Price To Earnings Diluted Ratio | -48.149 | ▼-65.958 | ▼-18.744 |
| Price To Earnings Diluted Growth Ratio | 0.285 | ▲0.425 | ▼-0.184 |
| Price To Book Ratio | 1.716 | ▲0.735 | ▲0.409 |
| Price To Sales Ratio | 2.382 | ▲1.035 | ▲0.453 |
| Price To Free Cash Flow Ratio | 39.555 | ▲24.371 | ▲1.946 |
| Price To Operating Cash Flow Ratio | 20.060 | ▲9.002 | ▲0.057 |
| Debt To Assets Ratio | 0.301 | ▼-0.042 | ▼-0.060 |
| Debt To Equity Ratio | 0.614 | ▼-0.095 | ▼-0.165 |
| Debt To Capital Ratio | 0.380 | ▼-0.035 | ▼-0.055 |
| Long Term Debt To Capital Ratio | 0.376 | ▼-0.036 | ▼-0.052 |
| Financial Leverage Ratio | 2.040 | ▼-0.029 | ▼-0.107 |
| Working Capital Turnover Ratio | 2.507 | ▲0.324 | ▼-0.096 |
| Operating Cash Flow Ratio | 0.351 | ▼-0.061 | ▲0.043 |
| Operating Cash Flow Sales Ratio | 0.119 | ▼-0.003 | ▲0.018 |
| Free Cash Flow Operating Cash Flow Ratio | 0.507 | ▼-0.221 | ▼-0.063 |
| Debt Service Coverage Ratio | 2.272 | ▼-1.224 | ▲0.838 |
| Interest Coverage Ratio | 1.145 | ▲0.405 | ▲0.003 |
| Short Term Operating Cash Flow Coverage Ratio | 7.568 | ▼-4.728 | ▲1.607 |
| Operating Cash Flow Coverage Ratio | 0.139 | ▲0.014 | ▲0.046 |
| Capital Expenditure Coverage Ratio | 2.029 | ▼-1.651 | ▼-0.447 |
| Dividend Paid And Capex Coverage Ratio | 2.029 | ▼-1.651 | ▼-0.447 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 21.754 | ▲15.148 | ▲15.287 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.23B | $5.98B | $7.34B | $5.97B | $13.83B | |
| Enterprise value | $14.71B | $9.84B | $12.76B | $11.46B | $19.51B | |
| EV / Sales | 3.12x | 2.22x | 2.89x | 2.60x | 4.09x | |
| EV / Op. cash flow | 26.26x | 18.18x | 47.08x | 25.35x | 40.39x | |
| EV / Free cash flow | 51.78x | 24.96x | 109.04x | 42.75x | 68.21x | |
| EV / EBITDA | 21.75x | 6.61x | -56.95x | 13.23x | 47.70x | |
| Net debt / EBITDA | 5.14x | 2.59x | -24.20x | 6.34x | 13.89x | |
| Current ratio | 2.17x | 2.44x | 2.75x | 1.93x | 1.99x | |
| Income quality | -2.41x | 1.60x | -0.22x | -5.79x | -1.02x | |
| Graham number | — | $14 | — | — | — | |
| Graham net-net | -$9 | -$9 | -$13 | -$13 | -$14 | |
| Tax burden | 103.6% | 69.3% | 103.0% | 108.3% | 84.6% | |
| Interest burden | 5600.0% | 59.0% | 130.2% | -39.1% | 186.0% | |
| Working capital | $1.86B | $1.90B | $2.17B | $1.58B | $1.63B | |
| Invested capital | $11.46B | $10.99B | $12.78B | $13.41B | $14.44B | |
| Return on assets | -1.7% | 2.7% | -8.6% | -0.5% | -2.9% | |
| Operating ROA | 1.9% | 1.9% | 2.2% | 2.4% | 1.8% | |
| Return on tangible assets | -4.5% | 7.5% | -25.8% | -1.7% | -10.2% | |
| Return on equity | -3.5% | 5.5% | -19.8% | -1.1% | -6.4% | |
| Return on invested capital | 2.1% | 1.5% | 2.5% | 2.7% | 1.7% | |
| Return on capital employed | 2.1% | 2.2% | 2.5% | 2.8% | 2.0% | |
| Earnings yield | -2.1% | 5.6% | -16.8% | -1.3% | -3.5% | |
| Free cash flow yield | 2.5% | 6.6% | 1.6% | 4.5% | 2.1% | |
| Capex / Op. cash flow | 49.3% | 27.2% | 56.8% | 40.7% | 40.8% | |
| Capex / Depreciation | 40.6% | 22.2% | 22.2% | 27.0% | 27.5% | |
| Capex / Sales | 5.9% | 3.3% | 3.5% | 4.2% | 4.1% | |
| SG&A / Sales | 30.3% | 29.6% | 29.1% | 28.7% | 29.5% | |
| R&D / Sales | 7.8% | 7.7% | 7.4% | 7.3% | 7.7% | |
| Stock comp / Sales | 1.4% | 1.2% | 1.0% | 1.3% | 1.4% | |
| Intangibles / Total assets | 61.3% | 64.2% | 66.8% | 69.9% | 71.4% | |
| Days sales outstanding | 73d | 73d | 83d | 83d | 79d | |
| Days payables outstanding | 50d | 43d | 40d | 58d | 56d | |
| Operating cycle | 311d | 300d | 339d | 313d | 265d | |
| Cash conversion cycle | 260d | 257d | 299d | 255d | 208d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+87.8%EV / Sales ▲+40.8%EV / EBITDA ▲+229.3%EV / Op. cash flow ▲+8.080Earnings yield ▼-0.077
Profitability
Return on equity ▼-0.091Return on assets ▼-0.044Return on invested capital ▲+0.006Return on capital employed ▼-0.001Operating ROA ▲+0.001Income quality ▼-4.014Tax burden ▲+0.343
Efficiency
Days sales outstanding ▼-0.084Days payables outstanding ▲+7.698Operating cycle ▲+10.737Cash conversion cycle ▲+3.039Capex / Sales ▲+0.025R&D / Sales ▲+0.001
Balance-sheet strength
Current ratio ▼-0.280Net debt / EBITDA ▲+2.548Working capital ▼-39000000.000Invested capital ▲+469000000.000Intangibles / Total assets ▼-0.029
Change over 5 years
Valuation
Market cap ▼-18.8%EV / Sales ▼-23.8%EV / EBITDA ▼-54.4%EV / Op. cash flow ▼-14.129Earnings yield ▲+0.014
Profitability
Return on equity ▲+0.029Return on assets ▲+0.012Return on invested capital ▲+0.004Return on capital employed ▲+0.001Operating ROA ▲+0.002Income quality ▼-1.390Tax burden ▲+0.190
Efficiency
Days sales outstanding ▼-5.994Days payables outstanding ▼-6.087Operating cycle ▲+45.740Cash conversion cycle ▲+51.827Capex / Sales ▲+0.017R&D / Sales ▲+0.001
Balance-sheet strength
Current ratio ▲+0.177Net debt / EBITDA ▼-8.754Working capital ▲+234000000.000Invested capital ▼-2984000000.000Intangibles / Total assets ▼-0.101
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-23 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-09-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-27 | Ro Khanna | Sale | $1,000 - $15,000 |
| 2025-08-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-06-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-22 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-12 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-04 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-05-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-04-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-03-06 | Daniel Goldman | Sale (Partial) | $1,001 - $15,000 |
| 2023-03-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-22 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-28 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-22 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-30 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2022-11-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-22 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-16 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-11-15 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-13 | Alan S. Lowenthal | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2021-06-21 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2021-06-10 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-12-21 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-11-06 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-05 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2020-10-22 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
| 2020-06-16 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-08-20 | Alan S. Lowenthal | Sale (Full) | $1,001 - $15,000 |
| 2019-08-20 | Alan S. Lowenthal | Sale (Full) | $15,001 - $50,000 |
| 2019-03-06 | Alan S. Lowenthal | Exchange | $1,001 - $15,000 |
| 2019-03-06 | Alan S. Lowenthal | Exchange | $1,001 - $15,000 |
Recent news
- 2026-08-19 Elanco Animal Health: New Products To Support Growth I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.
- 2026-08-19 Director''s Confidence Visible as Elanco Leader Buys 10,000 Shares The director upped their stake by 10,000 shares. This purchase increased the insider''s direct equity holdings by 10%.
- 2026-08-19 Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC''s ‘Final Trades'' On CNBC''s “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, recommended Netflix, Inc. (NASDAQ:NFLX).
- 2026-08-12 Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN''s innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis'' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program and strong cash flow; net leverage is targeted below 3.0x by 2027.
- 2026-08-08 Elanco Animal Health Q2 Earnings Call Highlights Elanco Animal Health NYSE: ELAN reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth.
- 2026-08-07 Elanco''s CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livest Elanco''s CLiK⢠Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds
- 2026-08-07 Elanco''s CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species Vigilance and early intervention are key to minimizing animal injury and limiting the parasite''s spread, according to Elanco''s technical experts Emergency Use Authorization for Elanco''s CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also offers producers Negasunt® Powder (coumaphos, propoxur, and sulfanilamide topical powder) and Tanidil®, which received emergency authorizations earlier this year, as well as EPA-registered Catron™ IV.
- 2026-08-07 Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN Amundi lifted its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 101.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,313 shares of the company''s stock after buying an additional 49,608 shares during the quarter. Amundi''s holdings in Elanco Animal Health
- 2026-08-06 Elanco Animal Health Inc (ELAN) Shares Fall 7.7% -- What GF Score of 66 Tells Investors On August 06, 2026, Elanco Animal Health Inc (ELAN) shares fell 7.7% to $24.20, continuing a challenging week where the stock has declined by 8.5%. Over the pas
- 2026-08-06 Elanco CEO on Boosted Forecast, Surge in Tick Bites Elanco Animal Health President and CEO Jeff Simmons discusses what''s behind the company''s increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent surge in tick bites and consumer spending on pet health products.